-
Viewing the market ceiling of digital therapy from Livongo
Time of Update: 2021-12-08
Judging from the development trend of the market, although the digital therapy focused on chronic disease management, especially in the field of diabetes management, has a large population base, for example, there are more than 30 million people with diabetes in the United States .
-
Beta amyloid is no longer the focus of clinical development AD R&D enters the era of great navigation
Time of Update: 2021-12-08
However, the Alzheimer’s Disease Drug Discovery Foundation (ADDF) recently released the "Alzheimer’s Disease Clinical Trial Report 2021" that based on a deeper understanding of the pathogenesis of aging and Alzheimer’s disease, the existing The R&D pipeline is no longer focused on Aβ and tau proteins, but on a variety of innovative targets .
-
How much does the medical insurance negotiation drug prescribe affect the assessment of medical institutions?
Time of Update: 2021-12-08
The health department should adjust and improve the evaluation mechanism for the use of drugs in medical institutions , and list the negotiated drugs that are reasonably used separately from the scope of evaluation indicators that affect their implementation, such as the proportion of drugs in medical institutions and the average cost per second .
-
Two Paths for the Development of Chinese Pharmaceutical Enterprises
Time of Update: 2021-12-08
Under the backing of capital, innovation (including true innovation and fake innovation) has become the fastest-growing segment of medicine; but everyone seems to ignore China’s role The cost dividend of the world manufacturing center starts with generic drugs, uses imitations to promote innovation, and finally enters world-class pharmaceutical companies.
-
Numbers ｜What is the current status of clinical trials for new drug registration in China?
Time of Update: 2021-12-08
Number of clinical trials Number of drug varieties Class 1 new drug Drug target Indication field 2602 items2602 items Year 2020 registered a total of clinical trials 2602 .
-
Medical Insurance Bureau: unified consumables recruitment platform for national linkage
Time of Update: 2021-12-08
Multi-province recruitment and acquisition data migration work in progressMulti-province recruitment and acquisition data migration work in progress A few days ago, Beijing issued the "Notice on the
-
The Drug Evaluation Center of the State Food and Drug Administration released the "Annual Report on the Current Status of Clinical Trials for New Drug Registration in China (2020)"
Time of Update: 2021-12-08
pdf1"Annual Report on the Current Status of Clinical Trials of New Drug Registration in China (2020)".
-
Let life be brighter!
Time of Update: 2021-12-07
A series of market reforms and new regulatory policies have also fully demonstrated the efforts made by China’s drug review departments, clinical researchers and pharmaceutical companies to meet medical needs and protect people’s health.
-
The total has reached 2.2 billion US dollars!
Time of Update: 2021-12-07
The positive clinical data of Merck's oral antiviral drug molnupiravir in the treatment of COVID-19 is continuing to bring great returns to the company .
This Wednesday, only one day after announcing that it had signed a $1 billion sales order with the US government, the company disclosed another major supply transaction .
-
The clinical progress of TCR-T therapy is gratifying!
Time of Update: 2021-12-07
In the field of cancer cell immunotherapy, CAR-T and TCR-T occupies half of the country . Compared with CAR-T, which has achieved outstanding results in the treatment of hematoma, for solid tumors,
-
15 innovative drugs have reached the primary endpoint in Phase 3 clinical trials, from companies such as AbbVie, Merck, AstraZeneca, Hengrui Pharmaceuticals, etc.!
Time of Update: 2021-12-07
On October 27, Hengrui Medicine announced that Adbelizumab combined with chemotherapy has reached the primary research endpoint in the Phase 3 clinical study of the first-line treatment of extensive-stage small cell lung cancer .
-
Compensation of 1.5 billion yuan!
Time of Update: 2021-12-07
By suppressing the development of immunosuppressive and immune-oncology drugs, Opdivo took advantage of new cancer treatments and decided to settle the final litigation in order to show the cooperation in the industry-academia in Japan.
In June last year, Honjo announced a lawsuit against Ono Pharmaceuticals because the latter owed 22 billion yen in patent fees .
-
Keji Pharmaceutical's CLDN18.2 CAR-T cell drug candidate obtained EMA priority drug qualification
Time of Update: 2021-12-07
On November 15, 2021, Keji Pharmaceuticals official website announced that its self-developed CT041 (an autologous CAR-T candidate for CLDN 18.
Keji Pharmaceutical has applied to the State Food and Drug Administration in China for the regulatory approval required to initiate a key phase II clinical trial .
-
Looking at the trend and end of digital therapy from the payer
Time of Update: 2021-12-07
From the perspective of the German model, even if digital therapy can be covered by medical insurance, it cannot promote its own scale, let alone the possibility of commercialization .
-
Biogen releases more Aduhelm biomarker data and its correlation with the clinical benefit of Alzheimer's disease
Time of Update: 2021-12-07
Radhakrishnan said that new data shows that removing amyloid aggregation with Aduhelm can reduce the level of soluble p-tau protein, thereby slowing down the accumulation of tau protein quality, thereby slowing down the decline in clinical cognition .
-
Announcement of the State Food and Drug Administration on the establishment of a centralized unit for medical high-throughput sequencing standardization technology (No. 137 of 2021)
Time of Update: 2021-12-07
In order to promote the high-quality development of the medical device industry, implement the "Opinions of the National Standardization Administration of the State Drug Administration on Further Promoting the High-Quality Development of Medical Device Standardization", and further improve the medical device standardization organization system, the State Food and Drug Administration has decided to establish a medical device The central unit of high-throughput sequencing standardization technology is hereby announced, and the composition plan is shown in the attachment .
-
How do medical insurance negotiations and centralized national procurement stir up the pharmaceutical market?
Time of Update: 2021-12-07
As a powerful measure to reduce drug prices in recent years, medical insurance negotiations and national centralized procurement have far-reaching influence .
In 2018, 17 anti-cancer drugs were included in the National Medical Insurance List through negotiations, with an average price reduction of 56.
-
2021 Basic Drug List Management Measures Released, National Health Commission's Department of Pharmaceutical Affairs, Public Solicitation of Comments
Time of Update: 2021-12-07
Article 11 The National Health Commission drafts the National Essential Drug List selection work plan in accordance with the law, formulates specific selection rules, solicits opinions from relevant departments and parties in accordance with the law, and is reviewed by the National Essential Drug Working Committee, organized and implemented in accordance with the procedures and announced to the public .
-
The focus of medical insurance negotiations-the way to "negotiation reserve price"
Time of Update: 2021-12-07
The reserve price is derived from the two groups of experts finally giving us two sets of data, one is the price of a pharmaceutical economist, and the other is the price of the medical insurance fund calculation group.
-
$1.24 billion!
Time of Update: 2021-12-07
On November 9, Pfizer announced that it had reached a cooperation with Biohaven to introduce the company's rights and interests in the company's oral CGRP antagonist Rimegepant (Nurtec®ODT) outside the United States .
